The goal of this study is to determine whether transcranial magnetic stimulation (TMS) is an effective treatment in decreasing craving in individuals who habitually smoke cigarettes. The study consists of six total visits to MUSC; one for the consent process, two that will include MRI scans, and five that will include TMS administration. Compensation will be provided for each visit.
This study will use cue exposure to update an individual's smoking-related memory with information that will decrease response to smoking cues. The goal is to alter existing smoking-related memory directly. Positive findings could lead to a treatment that uniquely targets cue-elicited craving and response in smokers, thereby addressing a major obstacle to successful quit attempts.
The purpose of this study is to develop repetitive transcranial magnetic stimulation (rTMS) as a potential treatment for opiate dependence addiction. Repetitive TMS is a non-invasive technique that uses magnetic pulses to temporarily stimulate specific brain areas in awake people (without the need for surgery, anesthetic, or other invasive procedures). This study will test whether rTMS over the prefrontal cortex can produce a reduction in your perception of pain, your desire to use opiates, and your brain’s response to opiate cues. TMS has been approved by the FDA as an investigational tool as well a therapy for depression.
Stress is likely involved in relapse to cocaine use. This project will investigate the role oxytocin may play in the stress response in cocaine-dependent men and women and examine how oxytocin may impact brain activity in individuals exposed to cocaine-related cues.
Previous studies suggest that pregnenolone may inhibit the intoxicating effects of marijuana and reduce drug-seeking behavior. In this study we are examining the effects of pregnenolone on craving and mood in response to marijuana cues. In addition we are examing the effects of pregnenolone on blood levels of endogenous endocannabinoids.
The purpose of this pilot study is to investigate alterations in neural activity among individuals with Tourettes Syndrome. This will be acheived with single-pulse transcranial magnetic stimulation (TMS) and magnetic resonance imaging (MRI). These techniques are non-invasive. TMS is a brain stimulation method that allows us to measure the speed of information processing between brain regions as well as between the brain and the muscles. Combine with MRI, these techniques allow us to create a dynamic image of brain activity which may help guide future treatments. It is important to note that this will be used for research purposes and is not diagnostic.
The Sleep Research Data Repository (SRDR) aimed to systematically collect, analyze and store for future research sleep and sleep disorders related biological and psychological information. It will include sleep physiological measurements and the results of interviews, questionnaires, and laboratory tests. The SRDR will contain sleep related information obtained from healthy subjects and patients with psychiatric, substance abuse, neurological disorders, or any medical conditions associated with sleep disturbances. SRDR data will be made available to current and future IRB-approved investigators associated with this protocol.
This study is designed to evaluate the efficacy, safety, and tolerability of ALKS 3831 in schizophrenia with AUD. ALKS 3831 is a combination of olanzapine, an approved antipsychotic treatment for schizophrenia, and samidorphan, a new medication. Potential subjects for this trial are adults with a diagnosis of schizophrenia and alcohol use disorder (AUD) with a recent change in symptoms. The study will test whether olanzapine with samidorphan will aide in lowering alcohol use for subjects at the same time that the combination of the two drugs lessens side effects of olanzapine such as weight gain.